Valuation: Modalis Therapeutics Corporation

Market Cap 3.44B 21.75M 19.09M 17.95M 16.41M 30.66M 2.08B 30.89M 216M 83.57M 1.06B 81.69M 79.9M P/E 2024
-3.57x
P/E 2025 -2.01x
Enterprise Value 632M 3.99M 3.51M 3.29M 3.01M 5.63M 383M 5.67M 39.57M 15.34M 195M 15M 14.67M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
91.39%
Yield 2024 *
-
Yield 2025 -
09-11 Exegenesis Bio and Modalis Therapeutics Corporation Collaborate To Advance MDL-201 For Duchenne Muscular Dystrophy CI
08-10 Modalis Therapeutics Corporation Reports Earnings Results for the Half Year Ended June 30, 2026 CI
06-12 Modalis Therapeutics Corporation announced that it has received ¥2.64 million in funding from Evolution Capital Management LLC CI
05-27 Modalis Therapeutics Corporation announced that it expects to receive ¥2.64 million in funding from Evolution Capital Management LLC CI
05-13 Modalis Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
02-12 Modalis Therapeutics Corporation Reports Earnings Results for the Full Year Ended December 31, 2025 CI
25/08/25 Modalis Therapeutics Corporation announced that it has received ¥3.072 million in funding from Evolution Capital Management LLC CI
07/08/25 Modalis Therapeutics Corporation announced that it expects to receive ¥3.072 million in funding from Evolution Capital Management LLC CI
07/07/25 Modalis Therapeutics Licenses Gene Therapy IP from Broad Institute for Muscular Dystrophy Treatment MT
16/06/25 Modalis Issues Restricted Stock to Subsidiary Employee Under Incentive Plan MT
09/06/25 SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy CI
01/05/25 Modalis Issues 21,900 Shares for Restricted Stock Remuneration MT
27/01/25 Modalis Therapeutics Secures Japanese Patent for Gene Therapy MT
Current month-2.94%
6 months-43.10%
Current year-41.07%
1 week 32
Extreme 32
34
1 month 32
Extreme 32
50
Current year 29
Extreme 29
83
1 year 29
Extreme 29
84
3 years 29
Extreme 29
203
5 years 29
Extreme 29
1,438
10 years 29
Extreme 29
4,070
Manager TitleAgeSince
Chief Executive Officer 57 01/01/2016
Director of Finance/CFO 63 -
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 57 01/01/2016
Director/Board Member 60 01/01/2016
Director/Board Member 68 01/01/2016
Date Insider Type Main position Quantity % Market Cap. Importance
24/09/24 Others

Founder

10,000 0.0220%
24/09/24 Others

Founder

10,000 0.0220%
24/09/24 Others

Founder

6,000 0.0132%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-59.26%-78.98% 21.75M
+0.06%+6.49%+60.29%+111.13% 74.18B
-0.43%-4.19%+33.70%+74.27% 59.55B
-2.05%-3.46%-18.60%+352.20% 25.84B
-2.39%+2.74%+0.19%-5.91% 24.73B
-0.83%+1.43%+21.87%-9.72% 20.87B
+1.29%-2.49%+152.11%+333.06% 15.32B
-2.44%-0.09%+42.50%+164.11% 14.06B
-3.91%-4.91%-14.10%+779.68% 13.12B
-1.12%-3.04%+15.72%+234.56% 11.85B
Average -1.19%-1.20%+23.44%+195.44% 25.95B
Weighted average by Cap. -0.90%+0.70%+36.17%+161.20%

Financials

2024 2025
Net sales - -
Net income -1.32B -8.32M -7.3M -6.86M -6.27M -11.72M -797M -11.81M -82.42M -31.95M -406M -31.23M -30.55M -2.15B -13.59M -11.93M -11.21M -10.25M -19.16M -1.3B -19.3M -135M -52.21M -664M -51.04M -49.92M
Net Debt -3.58B -22.58M -19.82M -18.63M -17.03M -31.82M -2.16B -32.06M -224M -86.74M -1.1B -84.78M -82.93M -2.81B -17.76M -15.59M -14.65M -13.4M -25.03M -1.7B -25.22M -176M -68.23M -867M -66.69M -65.23M
Logo Modalis Therapeutics Corporation
Modalis Therapeutics Corp is a Japan-based company engaged in the research and development of gene therapy drugs using the core platform CRISPR-GNDM technology. The Company develops gene therapy drugs that use CRISPR-GNDM technology, which is a unique platform technology, for genetic diseases caused by errors in the genetic code and epigenetics. The Company has two business models. Collaborative model pipeline opens CRISPR-GNDM technology to partners, and develops therapeutic drugs with partners' funds for the targets selected by the partners. In-house model pipeline selects targets using the Company's own CRISPR-GNDM technology and develops therapeutic agents. The Company's pipeline consists of a collaborative model pipeline of 5 items such as MDL-201 and an in-house model pipeline of 2 items such as MDL-101.
Employees
-
Date Price Change Volume
24/09/26 ¥33.00 0.00% 886,600
18/09/26 ¥33.00 0.00% 961,300
17/09/26 ¥33.00 0.00% 869,500
16/09/26 ¥33.00 +3.12% 1,345,900
15/09/26 ¥32.00 -3.03% 1,898,000

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4883 Stock